Literature DB >> 31278540

Association between rs10046, rs1143704, rs767199, rs727479, rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms in aromatase (CYP19A1) gene and Alzheimer's disease risk: a systematic review and meta-analysis involving 11,051 subjects.

Yuxuan Song1, Yi Lu1, Zhen Liang1, Yongjiao Yang1, Xiaoqiang Liu2.   

Abstract

BACKGROUND: CYP19A1 enzyme (aromatase) encoded by CYP19A1 (cytochrome p450 family 19 subfamily a member 1) gene plays a key role in the biosynthesis of estrogen, which has been significantly associated with Alzheimer's disease (AD). To ascertain whether CYP19A1 gene polymorphisms are correlated with the susceptibility to AD, we performed this systematic review and meta-analysis of currently available studies.
MATERIALS AND METHODS: A comprehensive literature search was conducted by using PubMed, Embase, and Web of Science databases and the Cochrane Library. The association was evaluated by using odds ratios (ORs) and 95% confidence intervals (CIs) through Stata software (version 12.0).
RESULTS: A total of eight articles including 39 case-control studies with 11,051 subjects including 3215 AD cases and 7836 controls were involved in this meta-analysis. By pooling all eligible studies, we detected that rs10046, rs1143704, rs767199, and rs727479 polymorphisms in CYP19A1 gene were significantly associated with AD risk. A significant association between rs10046 polymorphism and AD risk was found under allele contrast, homozygous (TT vs CC: OR = 1.17, 95%CI = 1.02-1.34, I2 = 0.0%, P = 0.026), and dominant genetic models. In addition, we observed an association between with rs1143704 polymorphism under heterozygous and dominant genetic models (TT+TA vs AA: OR = 1.36, 95%CI = 1.03-1.79, I2 = 0.0%, P = 0.033). Similar results were found in rs767199 and rs727479 polymorphisms, while null results were found for other polymorphisms.
CONCLUSIONS: This systematic review and meta-analysis suggested that the rs10046, rs1143704, rs767199, and rs727479 polymorphisms in CYP19A1 gene significantly increase AD susceptibility. In addition, our results demonstrated that homozygous TT genotype in rs10046, dominant AA and AG genotypes in rs767199, homozygous TT genotype in rs727479, and dominant TT and TA genotypes in rs1143704 might be the susceptibility genotypes for AD, while no associations were observed between rs1065778, rs1062033, rs1008805, and rs700519 polymorphisms and AD susceptibility.

Entities:  

Keywords:  Alzheimer’s disease; Aromatase; Meta-analysis; Polymorphism; Systematic review

Mesh:

Substances:

Year:  2019        PMID: 31278540     DOI: 10.1007/s10072-019-04003-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  38 in total

1.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

2.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses.

Authors:  Andreas Stang
Journal:  Eur J Epidemiol       Date:  2010-07-22       Impact factor: 8.082

3.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

Review 4.  Alzheimer's disease.

Authors:  C A Lane; J Hardy; J M Schott
Journal:  Eur J Neurol       Date:  2017-10-19       Impact factor: 6.089

5.  Estrogen regulates metabolism of Alzheimer amyloid beta precursor protein.

Authors:  A B Jaffe; C D Toran-Allerand; P Greengard; S E Gandy
Journal:  J Biol Chem       Date:  1994-05-06       Impact factor: 5.157

6.  Effects of estrogen treatment on glutamate uptake in cultured human astrocytes derived from cortex of Alzheimer's disease patients.

Authors:  Zhe Liang; Jon Valla; Sepideh Sefidvash-Hockley; Joseph Rogers; Rena Li
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

7.  2016 Alzheimer's disease facts and figures.

Authors: 
Journal:  Alzheimers Dement       Date:  2016-04       Impact factor: 21.566

8.  Polymorphisms in the CYP19 gene confer increased risk for Alzheimer disease.

Authors:  S Iivonen; E Corder; M Lehtovirta; S Helisalmi; A Mannermaa; S Vepsäläinen; T Hänninen; H Soininen; M Hiltunen
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

9.  The sex-specific associations of the aromatase gene with Alzheimer's disease and its interaction with IL10 in the Epistasis Project.

Authors:  Christopher Medway; Onofre Combarros; Mario Cortina-Borja; Helen T Butler; Carla A Ibrahim-Verbaas; Renée F A G de Bruijn; Peter J Koudstaal; Cornelia M van Duijn; M Arfan Ikram; Ignacio Mateo; Pascual Sánchez-Juan; Michael G Lehmann; Reinhard Heun; Heike Kölsch; Panos Deloukas; Naomi Hammond; Eliecer Coto; Victoria Alvarez; Patrick G Kehoe; Rachel Barber; Gordon K Wilcock; Kristelle Brown; Olivia Belbin; Donald R Warden; A David Smith; Kevin Morgan; Donald J Lehmann
Journal:  Eur J Hum Genet       Date:  2013-06-05       Impact factor: 4.246

10.  Genetic polymorphism at Val80 (rs700518) of the CYP19A1 gene is associated with aromatase inhibitor associated bone loss in women with ER + breast cancer.

Authors:  Nicola Napoli; Antonella Rastelli; Cynthia Ma; Jayasree Yarramaneni; Swapna Vattikutti; Gerard Moskowitz; Tusar Giri; Cheryl Mueller; Vibhati Kulkarny; Clifford Qualls; Matthew Ellis; Reina Armamento-Villareal
Journal:  Bone       Date:  2013-05-01       Impact factor: 4.398

View more
  2 in total

Review 1.  Aromatase in the Human Brain.

Authors:  Iñigo Azcoitia; Pablo Mendez; Luis M Garcia-Segura
Journal:  Androg Clin Res Ther       Date:  2021-12-23

2.  Estrogen receptor beta (ESR2) gene polymorphism and susceptibility to dementia.

Authors:  Zulvikar Syambani Ulhaq; Cristian Peinado Garcia
Journal:  Acta Neurol Belg       Date:  2020-04-25       Impact factor: 2.396

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.